Update: Redefined and refined
Wilex has fulfilled its target of establishing global licence deals for Mesupron, opening up the opportunity to confirm its potential across a range of oncology indications. The new, leaner Wilex is focusing on its antibody drug conjugate ADC technology and targets additional alliances along the lines of its existing tie-up with Roche. It also seeks partners for the clear cell renal cancer programme. Our valuation is €46m, which could increase to €116m if Wilex can out-license Rencarex and Redectane.Wilex is a biopharmaceutical company focused on oncology and antibodies. The parent company WILEX AG no longer pursues clinical development activities in Munich, instead acting exclusively as a holding company. Operation concentrate on the research and development activities of the subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma workes with the toxin Amanitin and an ADC technology with the goal of coupling this highly effective agent with various antibodies to make it usable for treating cancer. This innovative technology platform is progressively being developed for therapeutic antibody drug conjugates for use in proprietary projects and partnerships.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.